KalVista Pharmaceuticals (KALV) Other Non-Current Liabilities (2014 - 2024)
KalVista Pharmaceuticals (KALV) reported Other Non-Current Liabilities of $4.4 million for Q4 2024, up 93.7% sequentially from $2.3 million in Q1 2015.
KalVista Pharmaceuticals (KALV) Other Non-Current Liabilities (2014 - 2024) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 3 years of Other Non-Current Liabilities data on file, last reported at $4.4 million in Q4 2024.
- For the quarter ending Q4 2024, Other Non-Current Liabilities changed N/A year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2024 stood at $4.4 million (changed N/A YoY), and the FY2014 full-year result was $1.5 million, changed N/A from the prior year.
- Other Non-Current Liabilities grew to $4.4 million in Q4 2024, from $2.3 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $4.4 million in Q4 2024 to a low of $4.4 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 4.43 Mn |
| Mar 31, 2015 | 2.29 Mn |
| Dec 31, 2014 | 1.50 Mn |